CN1270713C - 一种用于预防或治疗糖尿病的协同药物组合物 - Google Patents

一种用于预防或治疗糖尿病的协同药物组合物 Download PDF

Info

Publication number
CN1270713C
CN1270713C CNB02814340XA CN02814340A CN1270713C CN 1270713 C CN1270713 C CN 1270713C CN B02814340X A CNB02814340X A CN B02814340XA CN 02814340 A CN02814340 A CN 02814340A CN 1270713 C CN1270713 C CN 1270713C
Authority
CN
China
Prior art keywords
pharmaceutical composition
formula
addition salts
insulin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02814340XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1531433A (zh
Inventor
Z·西尔瓦希
G·劳布洛茨基
P·利泰拉蒂纳吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
N-Gene Research Laboratories Inc
Original Assignee
N-Gene Research Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N-Gene Research Laboratories Inc filed Critical N-Gene Research Laboratories Inc
Publication of CN1531433A publication Critical patent/CN1531433A/zh
Application granted granted Critical
Publication of CN1270713C publication Critical patent/CN1270713C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
CNB02814340XA 2001-07-17 2002-07-10 一种用于预防或治疗糖尿病的协同药物组合物 Expired - Fee Related CN1270713C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HUP0102982 2001-07-17
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
HUP0202204 2002-07-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200610051370.3A Division CN1840195A (zh) 2001-07-17 2002-07-10 一种用于预防或治疗糖尿病的协同药物组合物

Publications (2)

Publication Number Publication Date
CN1531433A CN1531433A (zh) 2004-09-22
CN1270713C true CN1270713C (zh) 2006-08-23

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02814340XA Expired - Fee Related CN1270713C (zh) 2001-07-17 2002-07-10 一种用于预防或治疗糖尿病的协同药物组合物

Country Status (21)

Country Link
US (2) US7635674B2 (https=)
EP (1) EP1408966B1 (https=)
JP (1) JP4598390B2 (https=)
KR (1) KR100920560B1 (https=)
CN (1) CN1270713C (https=)
AT (1) ATE386523T1 (https=)
AU (1) AU2002354884B2 (https=)
BR (1) BR0210744A (https=)
CA (2) CA2682251A1 (https=)
CY (1) CY1107939T1 (https=)
DE (1) DE60225143T2 (https=)
DK (1) DK1408966T3 (https=)
ES (1) ES2300460T3 (https=)
IL (2) IL159412A0 (https=)
MX (1) MXPA04000324A (https=)
NO (1) NO20040153L (https=)
NZ (1) NZ531155A (https=)
PL (1) PL205826B1 (https=)
PT (1) PT1408966E (https=)
RU (1) RU2311907C2 (https=)
WO (1) WO2003007951A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044531A2 (en) * 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
WO2012142458A1 (en) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN115916202A (zh) * 2020-05-27 2023-04-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c9底物的并行给药
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
DE60225143T2 (de) 2009-02-12
IL159412A (en) 2009-09-22
RU2311907C2 (ru) 2007-12-10
EP1408966A1 (en) 2004-04-21
JP4598390B2 (ja) 2010-12-15
AU2002354884A2 (en) 2003-03-03
US20100048627A1 (en) 2010-02-25
ATE386523T1 (de) 2008-03-15
US20070015687A1 (en) 2007-01-18
MXPA04000324A (es) 2004-07-23
BR0210744A (pt) 2004-07-20
CN1531433A (zh) 2004-09-22
PL205826B1 (pl) 2010-05-31
KR100920560B1 (ko) 2009-10-08
DE60225143D1 (de) 2008-04-03
CA2682251A1 (en) 2003-01-30
IL159412A0 (en) 2004-06-01
CA2452558A1 (en) 2003-01-30
PT1408966E (pt) 2008-05-02
ES2300460T3 (es) 2008-06-16
PL364662A1 (en) 2004-12-13
EP1408966B1 (en) 2008-02-20
US7635674B2 (en) 2009-12-22
JP2004537550A (ja) 2004-12-16
RU2004105149A (ru) 2005-04-20
DK1408966T3 (da) 2008-06-16
US8048873B2 (en) 2011-11-01
KR20040029371A (ko) 2004-04-06
NZ531155A (en) 2005-07-29
CY1107939T1 (el) 2013-09-04
WO2003007951A1 (en) 2003-01-30
NO20040153L (no) 2004-03-16
CA2452558C (en) 2009-12-22
AU2002354884B2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CN1270713C (zh) 一种用于预防或治疗糖尿病的协同药物组合物
CN1142783C (zh) 用于治疗高危葡萄糖耐量降低的药剂
CN1196488C (zh) 3－羟基－3－甲基戊二酸单酰辅酶a还原酶抑制剂制造治疗糖尿病性神经病的药物的应用
CN1642559A (zh) 含有HMG CoA还原酶抑制剂和胰岛素分泌促进剂或胰岛素增敏剂的组合
JP2008533044A (ja) 内皮機能不全、アンギナおよび糖尿病のための組合せ治療
CN1838949A (zh) 包含二甲双胍和他汀的组合的药物组合物
JP2004537550A5 (https=)
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CN1738611A (zh) 用作抗偏头痛剂的α－氨基酰胺衍生物
CN1840195A (zh) 一种用于预防或治疗糖尿病的协同药物组合物
CN1263467A (zh) 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
JP2006523668A (ja) 糖尿病の予防又は治療のためのシクレタニンを含有する相乗作用の薬学的組合せ
CN1192140A (zh) 氨基磺酸衍生物、酰基磺酰氨或磺酰基氨基甲酸酯在制备降低脂蛋白水平的药物中的用途
CN1655846A (zh) Pde抑制剂与白三烯受体拮抗剂的并用药物
CN1592615A (zh) 含有二甲双胍和4－氧代丁酸的药物组合物及其在治疗糖尿病中的用途
CN1917865A (zh) 有机化合物的组合
CN1655822A (zh) 含有acat抑制剂和胰岛素抵抗性改善剂的药用组合物
EP1526894B1 (en) Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment
CN1761467A (zh) 2－取代－吡啶－甲胺衍生物在制备用于治疗神经性和心理性慢性疼痛症状的药物的用途
CN1599608A (zh) 含有格列酮和4－氧代丁酸的药物组合物以及它们治疗糖尿病的用途
HUP0400762A2 (hu) Gyógyászati készítmény a diabetesz megelőzésére vagy kezelésére
KR20070104913A (ko) 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
EP1388351A1 (en) Use of fibrate to treat weight gain associated with rosiglitazone treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Instruction fourth

Correct: The correct instructions, page fourth

False: Incorrect instructions, fourth pages

Number: 34

Volume: 22

ERR Gazette correction

Free format text: CORRECT: PAGE 4 IN SPECIFICATION; FROM: PAGE 4 IN ERROR INSTRUCTION TO: PAGE 4 OF CORRECT SPECIFICATION

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060823

Termination date: 20150710

EXPY Termination of patent right or utility model